

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.)

SERIAL NO.: 09/918,127)

FILED: July 30, 2001)

FOR: Pharmaceutical Compositions of)
Cholesteryl Ester Transfer)
Protein Inhibitors)

Examiner: Fubara, Blessing M.

Art Unit: 1615

Commissioner for Patents
Washington, D.C. 20231

Sir:

DECLARATION UNDER 37 CFR 1.131

I, Douglas A. Lorenz, declare that:

1. This declaration is to establish completion of the invention of this application in the United States at a date prior to February 10, 1999, that is the effective date of U.S. Patent 6,706,283 that was cited by the examiner.
2. I am one of the inventors of the instant application.
3. To establish the date of completion of the invention of this application, reproductions of notebook entries are submitted as evidence as Exhibits A and B.
4. From these documents it can be seen that the invention in this application was made in the United States at least by the date of February 9, 1999, which is a date earlier than the effective date of the reference.

BEST AVAILABLE COPY


5. In particular attached to this declaration are notebook pages related to work I performed and supervised in connection with the process used to form solid amorphous dispersions of a cholesteryl ester transfer protein (CETP) inhibitor. The notebook pages attached as Exhibit A show that a CETP inhibitor was spray dried with the polymers hydroxypropylmethyl cellulose acetate succinate (HPMCAS), hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose (HPMC), polyvinylpyrrolidone (PVP), cellulose acetate phthalate (CAP) and cellulose acetate trimellitate (CAT) to form a solid amorphous dispersion. The notebook pages attached as Exhibit B show that the solid amorphous dispersion particles were dissolution tested and showed concentration-enhancement relative to the crystalline drug alone. This work was performed prior to February 9, 1999.

DECLARATION

6. As a person signing below:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Douglas A. Lorenz

Date: 10 - 13 - 04

NOTEBOOK NO. 1659
ISSUED TO Doug Lorenz
ON _____ 19____
DEPARTMENT _____
RETURNED _____ 19____

—SCIENTIFIC NOTEBOOK CO.—
2831 LAWRENCE AVE.
P.O. BOX 238
STEVENSVILLE, MI 49127
616-429-8285

118

TEMPLATE FOR EXPERIMENTAL WORK

Overall Hypothesis

Physical Model of Technology or Problem

Determine the feasibility of using high energy forms of CP-529,414 to increase the solubility + bioavailability of the drug.

Specific Study Goals

What is the key question about the hypothesis these experiments will answer?

What CP-529,414: polymer HED's have best dissolution performance during initial screening?

Experimental

Key Experimental Conditions

- mini spray dryer
 $T = 100^{\circ}\text{C} / 30^{\circ}\text{C}$, $P = 30 \text{ PSig}$, flow = 30 gauge reading,
Rate = 1.3 mL/min

Results/Conclusions

Key Results: Did we strengthen or weaken the hypothesis?

Spray went OK - See performance + potency data on later pages.

Graphs/Sketches

Estimate Trends of Key Experiment(s)

Witnessed & Understood by me,

[Signature]

Date

Redacted

Invented by

Recorded by

[Signature]

Date

Redacted

Project No. _____

Book No. _____

119

TITLE _____

From Page No. _____

CP-529414 HEDS-(1659-119)

1659-119a

3.0 mg CP-529414 (AN36721-145-2)

27 mg HPMCAS-LF (302022)

10 g acetone

1659-119b

27 mg HPMCAS-MF (203002)

3.0 mg CP-529414

10 g acetone

1659-119h

3.0 mg CP-529414

27 mg CAT (21201)

10 g acetone

1659-119c

3.0 mg CP-529414

27 mg HPMCAS-HF (312060)

10 g acetone

1659-119d

3.0 mg CP-529414

27 mg HPMCP (408343)

10 g acetone

1659-119e

3.0 mg CP-529414

27 mg HPMC (E3 Prem - M492071021E)

10 g acetone/MeOH 1/1

1659-119f

3.0 mg CP-529414

27 mg PVP K-29/32 (TX40430C)

10 g acetone/MeOH 9/1

1659-119g

3.0 mg CP-529414

27 mg CAP (60616)

10 g acetone

To Page No. _____

Witnessed & Understood by me,

Date

Invented by

Date

Redacted

Recorded by

Redacted

128

TEMPLATE FOR EXPERIMENTAL WORK

Graphs/Sketches

Estimate Trends of Key Experiment(s)

Overall Hypothesis

Physical Model of Technology or Problem

Determine the feasibility of using high energy forms of CP-529,414 to increase the solubility and bioavailability of the drug.

Specific Study Goals

What is the key question about the hypothesis these experiments will answer?

What is the PBS dissolution performance (initial screening) of 10% CP-529,414: polymer HEDs + what HED(s) give best performance?

Experimental

Key Experimental Conditions

Outlined @ right w/ additional experimental detail outlined in 1454-139 HRN LB.

Results/Conclusions

Key Results: Did we strengthen or weaken the hypothesis?

CAP, CAT + MF HEDs appear to be most promising in PBS receptor solution.

Witnessed & Understood by me,

[Signature]

Date

Redacted

Invented by

Recorded by

[Signature]

Date

Redacted

TITLE _____

From Page No. _____

10% CP-529,414 polymer HEDs —

Performance initial screening —

PBS receptor solution —

Theor $C_{max} \approx 100 \mu\text{g/mL}$

See disso results att'd below + results/
conclusions @ left

Title Dissolution Performance of 10% CP-529,414 HEDs With Various Polymers in PBS

Drug 1.8 mg CP-529,414-HPMCAS-LF 10%HED (BRI Ref. No. 1854-137)
1.8 mg CP-529,414-HPMCAS-MF 10%HED (BRI Ref. No. 1854-1198)
1.8 mg CP-529,414-HPMC 10%HED (BRI Ref. No. 1854-1192)

Receptor Solution 1.8 mL PBS, pH 6.5, 230 mOsm

Date Performed Redacted Notebook 1854-139


Operator HRN

Objective Determine dissolution performance of 10% CP-529,414 HEDs made with HPMCAS-LF, HPMCAS-MF, and HPMC in PBS.

Methods Micro Centrifuge Method. Drug potency and dissolution performance measured by HPLC.

Comments All work performed in a 37°C temperature controlled box.

Sample	C_{max} ($\mu\text{g/mL}$)	AUC ₀₋₈ ($\mu\text{g}\cdot\text{h/mL}$)	$C_{50\%}$ ($\mu\text{g/mL}$)	Theor C_{max} ($\mu\text{g/mL}$)
LF	78	5,900	17	87
MF	77	6,500	31	102
HPMC	70	4,800	18	111



Conclusions HEDs made with LF and MF have the good dissolution performance. However, HEDs made with CAP and CAT have better dissolution performance.

Title Dissolution Performance of 10% CP-529,414 HEDs With Various Polymers and Drug Alone in PBS

Drug 1.8 mg CP-529,414-CAP 10%HED (BRI Ref. No. 1858-1190)
1.8 mg CP-529,414 CAT 10%HED (BRI Ref. No. 1858-1194)
0.18 mg CP-529,414 (Lot No. 38721-145-2)

Receptor Solution 1.8 mL PBS, pH 6.5, 230 mOsm

Date Performed Redacted Notebook 1854-138


Operator HRN

Objective Determine dissolution performance of 10% CP-529,414 HEDs made with CAP and CAT in PBS. Compare to dissolution performance of drug alone in PBS.

Methods Micro Centrifuge Method. Drug potency and dissolution performance measured by HPLC.

Comments All work performed in a 37°C temperature controlled box.

Sample	C_{max} ($\mu\text{g/mL}$)	AUC ₀₋₈ ($\mu\text{g}\cdot\text{h/mL}$)	$C_{50\%}$ ($\mu\text{g/mL}$)	Theor C_{max} ($\mu\text{g/mL}$)
CAP	84	7,120	33	99
CAT	89	7,000	26	103
Drug Alone	4	300	2	100



Conclusions HEDs made with CAP and CAT have very similar dissolution profiles and perform much better than drug alone.

To Page No. _____

Witnessed & Understood by me,

[Signature]

Date, ,

Redacted

Invented by

Recorded by

[Signature]

Date

Redacted

NOTEBOOK NO. 1654
ISSUED TO Holly Neighbarger
ON Redacted 19 Redacted
DEPARTMENT
RETURNED 19

Mag= 20.00 K H
ENT=15.00 kV

Bond Research, Inc.

WD= 4 mm
288nm

c:\images\hrn 001

1 Probe = 25 pA

138

TEMPLATE FOR EXPERIMENTAL WORK

Graphs/Sketches

Estimate Trends of Key Experiment(s)

Overall Hypothesis

Physical Model of Technology or Problem

Specific Study Goal

What is the key question

Title Dissolution Performance of 10% CP-529,414 HEDs With Various Polymers and Drug Alone in PBS

Drug 1.8 mg CP-529,414:CAP 10%HED (BRI Ref. No. 1659-119G)
1.8 mg CP-529,414:CAT 10%HED (BRI Ref. No. 1659-119H)
0.18 mg CP-529,414 (Lot No. 36721-145-2)

Receptor Solution 1.8 mL PBS, pH 6.5, 290 mOsm

Data Performed Redacted Notebook 1654-139

Operator HRN


Objective Determine dissolution performance of 10% CP-529,414 HEDs made with CAP and CAT in PBS. Compare to dissolution performance of drug alone in PBS.

Methods Micro Centrifuge Method. Drug potency and dissolution performance measured by HPLC.

Comments All work performed in a 37°C temperature controlled box.

Results

Sample	C _{max} (µg/mL)	AUC ₀₋₆₀ (min*µg/mL)	C ₁₂₀₀ (µg/mL)	Theor C _{max} (µg/mL)
CAP	86	7,100	32	99
CAT	89	7,000	26	103
Drug Alone	4	300	2	100



HRN of MFDSmt
D. M.

Experimental

Key Experimental Condition

Standard
with

Results/Conclusions

Key Results: Did we strea

Conclusions HEDs made with CAP and CAT have very similar dissolution profiles and perform much better than drug alone.

Plans

Witnessed & Understood by me,

Joe B...

Date

Redacted

Invented by

Redacted

Date

Redacted

138

hes

if Key Experiment(s)

Overall Hypothesis

Physical Model of Test

Specific Study Goals

What is the key question?

Title Dissolution Performance of 10% CP-529,414 HEDs With Various Polymers in PBS

Drug 1.8 mg CP-529,414:HPMCAS-LF 10%HED (BRI Ref. No. 1654-137)
1.8 mg CP-529,414:HPMCAS-MF 10%HED (BRI Ref. No. 1654-119B)
1.8 mg CP-529,414:HPMC 10%HED (BRI Ref. No. 1654-119E)

Receptor Solution 1.8 mL PBS, pH 6.5, 290 mOsm

Date Performed Redacted Notebook 1654-139


Operator HRN

Objective Determine dissolution performance of 10% CP-529,414 HEDs made with HPMCAS-LF, HPMCAS-MF, and HPMC in PBS.

Methods Micro Centrifuge Method. Drug potency and dissolution performance measured by HPLC.

Comments All work performed in a 37°C temperature controlled box.

Sample	C _{max} (µg/mL)	AUC ₀₋₉₀ (min*µg/mL)	C ₁₂₀₀ (µg/mL)	Theor C _{max} (µg/mL)
LF	78	5,900	17	87
MF	77	6,500	51	102
HPMC	70	4,600	18	111



Handwritten note: 10% MF D50w

Experimental

Key Experimental Conditions

Handwritten note: standard method

Results/Conclusions

Key Results: Did we succeed?

Conclusions HEDs made with LF and MF have the good dissolution performance. However, HEDs made with CAP and CAT have better dissolution performance.

Plans

Handwritten initials: HRN

Witnessed & Understood by me,

Signature: Joe Bal

Date

Redacted

Invented by

Signature: [Redacted]

Date

Redacted

138

IS
Key Experiment(s)

Overall Hypothesis
Physical Model of Tech

Specific Study Goals

What is the key question about the hypothesis these experiments will answer?

Experimental

Key Experimental Conditions

Standard micro centrifuge disc - PBS instead of MFDSm!
method P.16 of this book

Results/Conclusions

Key Results: Did we strengthen or weaken the hypothesis?

(N)

Witnessed & Understood by me,

Date

Invented by

Date

Redacted

Redacted

TITLE Disso CP 529414 PBS

From Page No. _____

Redacted

PBS { 1 a + b 1.80 mg 10% CP 529414: LF (1654-137)
2 a + b " " : MF (1659-119B)
3 a + b " " : HPMC (1659-119E)
4 a + b " " : CAP (1659-119G)
5 a + b " " : CAT (1659-119H)
6 a + b 0.18 mg CP 529414 (N/A 36721-145-2)
MFPS 7 a + b 1.80 mg 10% CP 529414: LF (1654-137)

1 LF 1654-137
2 MF 1659-119B
3 HPMC 1659-119E
4 CAP 119G
5 CAT 119H
6 drug alone
36721-145-2

To Page No. _____

Witnessed & Understood by me,

[Signature]

Date

Redacted

Invented by

Recorded by

[Signature]

Date

Redacted

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.